Biote (BTMD) Q2 FY26 earnings call

Biote Corp. faced significant headwinds in Q2 FY26, primarily due to the lingering effects of a voluntary product recall which impacted procedure revenue and gross margin, leading to a downward revision of full-year guidance. Despite these financial challenges, the company has normalized supply at Asteria Health and is focusing on strategic initiatives in the second half, including strengthening clinic retention and sales productivity, alongside evaluating inorganic growth opportunities to expand its platform.